Salarius Pharmaceuticals Stock Total Debt

SLRX Stock

USD 1.37 0.09 6.16%

Salarius Pharmaceuticals fundamentals help investors to digest information that contributes to Salarius Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Salarius Stock. The fundamental analysis module provides a way to measure Salarius Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Salarius Pharmaceuticals stock.

Other Current Liab Total Assets

Total Debt To Capitalization is likely to drop to 0.03 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Salarius Pharmaceuticals Company Total Debt Analysis

Salarius Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Total Debt

Bonds

+

Notes

More About Total Debt | All Equity Analysis

Current Salarius Pharmaceuticals Total Debt

289.64 K

Most of Salarius Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Salarius Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Salarius Total Debt Driver Correlations

Understanding the fundamental principles of building solid financial models for Salarius Pharmaceuticals is extremely important. It helps to project a fair market value of Salarius Stock properly, considering its historical fundamentals such as Total Debt. Since Salarius Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Salarius Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Salarius Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Intangible Assets	Net Invested Capital	Net Working Capital	Capital Stock	Good Will	Short Long Term Debt	Short Term Debt
Total Assets		0.74	-0.87	0.24	0.39	0.11	0.99	0.26	0.46	0.52	0.43	0.5	-0.64	-0.44	-0.56	0.7	0.73	0.42	0.52	0.41	0.41
Total Stockholder Equity	0.74		-0.41	-0.25	0.58	-0.58	0.71	0.56	-0.2	0.06	0.16	-0.17	-0.09	-0.02	-0.06	0.25	0.2	0.27	0.18	0.03	0.03
Net Debt	-0.87	-0.41		-0.43	-0.07	-0.45	-0.88	-0.05	-0.8	-0.6	-0.4	-0.8	0.71	0.59	0.64	-0.72	-0.79	-0.42	-0.48	-0.39	-0.39
Retained Earnings	0.24	-0.25	-0.43		-0.41	0.65	0.17	-0.23	0.72	-0.05	0.31	0.63	-0.33	0.15	-0.08	0.47	0.35	0.21	0.35	0.24	0.24
Accounts Payable	0.39	0.58	-0.07	-0.41		-0.38	0.39	0.3	-0.4	0.23	0.34	-0.27	-0.25	-0.1	-0.21	0.25	0.26	0.06	0.18	0.19	0.19
Total Liab	0.11	-0.58	-0.45	0.65	-0.38		0.15	-0.52	0.84	0.54	0.29	0.86	-0.65	-0.5	-0.59	0.48	0.59	0.11	0.37	0.46	0.46
Total Current Assets	0.99	0.71	-0.88	0.17	0.39	0.15		0.16	0.48	0.6	0.38	0.54	-0.69	-0.54	-0.62	0.65	0.73	0.34	0.46	0.42	0.42
Common Stock	0.26	0.56	-0.05	-0.23	0.3	-0.52	0.16		-0.36	-0.14	0.22	-0.43	0.25	0.19	0.17	0.38	0.16	0.79	0.32	-0.18	-0.18
Net Tangible Assets	0.46	-0.2	-0.8	0.72	-0.4	0.84	0.48	-0.36		0.5	0.26	0.97	-0.67	-0.51	-0.56	0.55	0.65	0.22	0.36	0.38	0.38
Capital Surpluse	0.52	0.06	-0.6	-0.05	0.23	0.54	0.6	-0.14	0.5		0.45	0.66	-0.72	-0.87	-0.99	0.52	0.73	0.24	0.59	0.72	0.72
Deferred Long Term Liab	0.43	0.16	-0.4	0.31	0.34	0.29	0.38	0.22	0.26	0.45		0.34	-0.21	-0.13	-0.54	0.6	0.52	0.46	0.74	0.53	0.53
Property Plant Equipment	0.5	-0.17	-0.8	0.63	-0.27	0.86	0.54	-0.43	0.97	0.66	0.34		-0.75	-0.6	-0.72	0.55	0.69	0.14	0.46	0.56	0.56
Current Deferred Revenue	-0.64	-0.09	0.71	-0.33	-0.25	-0.65	-0.69	0.25	-0.67	-0.72	-0.21	-0.75		0.72	0.73	-0.69	-0.86	-0.19	-0.36	-0.48	-0.48
Net Receivables	-0.44	-0.02	0.59	0.15	-0.1	-0.5	-0.54	0.19	-0.51	-0.87	-0.13	-0.6	0.72		0.82	-0.42	-0.69	-0.16	-0.23	-0.34	-0.34
Intangible Assets	-0.56	-0.06	0.64	-0.08	-0.21	-0.59	-0.62	0.17	-0.56	-0.99	-0.54	-0.72	0.73	0.82		-0.57	-0.76	-0.24	-0.67	-0.78	-0.78
Net Invested Capital	0.7	0.25	-0.72	0.47	0.25	0.48	0.65	0.38	0.55	0.52	0.6	0.55	-0.69	-0.42	-0.57		0.93	0.79	0.73	0.41	0.41
Net Working Capital	0.73	0.2	-0.79	0.35	0.26	0.59	0.73	0.16	0.65	0.73	0.52	0.69	-0.86	-0.69	-0.76	0.93		0.62	0.62	0.45	0.45
Capital Stock	0.42	0.27	-0.42	0.21	0.06	0.11	0.34	0.79	0.22	0.24	0.46	0.14	-0.19	-0.16	-0.24	0.79	0.62		0.64	0.13	0.13
Good Will	0.52	0.18	-0.48	0.35	0.18	0.37	0.46	0.32	0.36	0.59	0.74	0.46	-0.36	-0.23	-0.67	0.73	0.62	0.64		0.81	0.81
Short Long Term Debt	0.41	0.03	-0.39	0.24	0.19	0.46	0.42	-0.18	0.38	0.72	0.53	0.56	-0.48	-0.34	-0.78	0.41	0.45	0.13	0.81		1.0
Short Term Debt	0.41	0.03	-0.39	0.24	0.19	0.46	0.42	-0.18	0.38	0.72	0.53	0.56	-0.48	-0.34	-0.78	0.41	0.45	0.13	0.81	1.0

Click cells to compare fundamentals

Salarius Total Debt Historical Pattern

Today, most investors in Salarius Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Salarius Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Salarius Pharmaceuticals total debt as a starting point in their analysis.

Salarius Pharmaceuticals Total Debt

Timeline

In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Competition

Predict Salarius Pharmaceuticals

Short Long Term Debt Total Over Time

Salarius Net Debt

Net Debt

(5.89 Million)

Salarius Pharmaceuticals reported Net Debt of (5.61 Million) in 2023

Based on the latest financial disclosure, Salarius Pharmaceuticals has a Total Debt of 289.64 K. This is 99.99% lower than that of the Biotechnology sector and 99.91% lower than that of the Health Care industry. The total debt for all United States stocks is 99.99% higher than that of the company.

Salarius Total Debt Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Salarius Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Salarius Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Salarius Pharmaceuticals by comparing valuation metrics of similar companies.

Salarius Pharmaceuticals is currently under evaluation in total debt category among its peers.

Salarius Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Salarius Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Salarius Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Salarius Pharmaceuticals' value.

		Shares
Vanguard Group Inc	2024-06-30	0.0
Geode Capital Management, Llc	2024-06-30	0.0
Armistice Capital, Llc	2024-06-30	22.8 K
Tower Research Capital Llc	2024-06-30	3.2 K
Ubs Group Ag	2024-06-30	113
Advisor Group Holdings, Inc.	2024-06-30	53.0
Morgan Stanley - Brokerage Accounts	2024-06-30	14.0
Bank Of America Corp	2024-06-30	6.0
Wells Fargo & Co	2024-06-30	1.0
Blackrock Inc	2024-06-30	1.0
Horizon Asset Management Inc/ny	2024-06-30	0.0

Salarius Fundamentals

	Return On Equity	-1.2
	Return On Asset	-0.54
	Current Valuation	(851.09 K)
	Shares Outstanding	1.44 M
	Shares Owned By Insiders	2.52 %
	Shares Owned By Institutions	0.36 %
	Number Of Shares Shorted	65.04 K
	Price To Book	0.72 X
	Price To Sales	18.12 X
	Gross Profit	(15.84 M)
	EBITDA	(12.88 K)
	Net Income	(12.54 M)
	Cash And Equivalents	22.65 M
	Cash Per Share	10.09 X
	Total Debt	289.64 K
	Debt To Equity	0 %
	Current Ratio	8.31 X
	Book Value Per Share	10.74 X
	Cash Flow From Operations	(12.85 M)
	Short Ratio	0.08 X
	Earnings Per Share	(5.14) X
	Target Price	26.0
	Beta	0.93
	Market Capitalization	2.1 M
	Total Asset	6.59 M
	Retained Earnings	(76.35 M)
	Working Capital	5.22 M
	Current Liabilities	1.97 M
	Net Asset	6.59 M

About Salarius Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Salarius Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Salarius Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Salarius Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Salarius Stock Analysis

When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC